Evidence map›Paper›PMID 39590310›Full record

ArticleCurrent issues in molecular biology2024

Comparative Analysis of Digital Transcriptomics Between Pre- and Post-Treatment Samples of Patients with Locally Advanced Cervical Cancer: A Preliminary Study.

Sunhwa Baek, Fabian Dominik Mairinger, Sabrina Borchert, Yue Zhao, Dominik Ratiu, Peter Konrad Mallmann, Henryk Pilch, Ka-Won Noh

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sunhwa BaekDepartment of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.ORCID 0009-0005-6297-5377
Fabian Dominik MairingerInstitute for Pathology, University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0003-1067-0051
Sabrina BorchertInstitute for Pathology, University Hospital Essen, 45147 Essen, Germany.
Yue ZhaoDepartment of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.ORCID 0000-0002-6790-3402
Dominik RatiuDepartment of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.
Peter Konrad MallmannDepartment of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.
Henryk PilchDepartment of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.
Ka-Won NohInstitute for Pathology, University Hospital Cologne and Medical Faculty, 50937 Cologne, Germany.ORCID 0000-0002-0041-9560

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a leading cause of cancer-related deaths in women worldwide, with limited treatment options for advanced stages and therapy-resistant cases. Despite advances in treatment, the variability in the patient response to standard therapies underscores the need for molecular biomarkers to guide personalized treatment strategies. This study aimed to explore the transcriptomic changes associated with the therapeutic response in locally advanced cervical cancer, focusing on 770 immune-related genes. We employed a digital multiplexed gene expression analysis, comparing gene expression profiles between matching pre- and post-treatment samples. The results revealed the significant upregulation of C7 and EGR2 in the post-treatment samples, suggesting that enhanced immune activity is a key factor in therapeutic success. Conversely, IL17RB, S100A7, and SAA1 were upregulated in the pre-treatment samples, potentially indicating resistance mechanisms. Pathway enrichment analysis highlighted that the immune response and apoptosis pathways are crucial to post-treatment changes. These findings suggest that C7, EGR2, and IL17RB may serve as biomarkers for predicting therapeutic outcomes and could inform the development of more effective, individualized treatment strategies for cervical cancer. This study provides new insights into the molecular mechanisms underlying treatment response and resistance.

Indexed as

cervical cancerdigital expression analysisprecision oncologytherapy resistance

Identifiers

PMID39590310
PMCPMC11592615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.